FLT3 mutations represent a cornerstone in the pathogenesis and treatment of AML. The integration of NGS into clinical workflows enhances mutation detection, risk stratification, and MRD monitoring.

Gilteritinib is a potent, well-tolerated oral FLT3 inhibitor approved as monotherapy for relapsed or refractory FLT3 -mutated AML. 23 The randomized, double-blinded, placebo-controlled Blood and ...

The FDA has approved Vanflyta (quizartinib) plus chemotherapy for adults with newly diagnosed AML that is FLT3-ITD positive.

FLT3- ITDs occur in 10-25% of newly diagnosed AML and generally confer unfavorable outcomes, particularly ITDs with a high allelic ratio and without NPM1 mutation. In the CALGB 10603/RATIFY trial ...

Some people with acute myeloid leukemia (AML) have a mutation in the FLT3 gene. Targeted therapies called FLT3 inhibitors can help treat AML in people with this mutation.

“These findings demonstrate the potential prognostic utility of FLT3 -ITD–specific MRD measurements in the clinical management of patients with FLT3 -ITD-positive AML,” investigators wrote.

Targeting rearranged during transfection (RET) proto-oncogene may be an effective therapeutic strategy for acute myeloid leukemia (AML) patients with mutations in FLT3 and activated RET. However, few ...

Background: Acute Myeloid Leukemia (AML) with FLT3-ITD mutations has poor prognosis and high relapse rates after allogeneic hematopoietic stem cell transplantation (allo-HCT). Post-transplant FLT3 ...

Researchers at Cincinnati Children's Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have disclosed IL-1 receptor-associated kinase 1 (IRAK-1) ...